1-for-35 Reverse Stock Split Set for Jaguar Health as Nasdaq Grants Delisting Extension
JAGX sits 20% above its 52-week low of $0.313.
Summary
Jaguar Health announced it will effect a 1-for-35 reverse stock split on April 30, 2026, to comply with Nasdaq's $1.00 bid price rule. The company also received an extension from Nasdaq until May 15, 2026, to demonstrate compliance. This action follows shareholder approval for potential reverse stock splits on April 21, 2026, and directly addresses the Nasdaq delisting threat highlighted in its recent 10-K. While the extension provides a temporary reprieve from delisting, the reverse split is a significant corporate action often indicative of a company facing financial challenges and does not resolve underlying business issues. Investors will closely watch if the company can maintain the required bid price post-split and for any further developments regarding its financial health.
At the time of this announcement, JAGX was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5M. The 52-week trading range was $0.31 to $15.48. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Access Newswire.